《大行報告》花旗下調康哲藥業(00867.HK)目標價至20元 評級「買入」
花旗發表報告指,康哲藥業(00867.HK)去年收入為92億元人民幣,按年增長10%,純利則按年上升8%至33億元人民幣。展望今年,管理層維持收入錄正增長的指引,主要受現有產品強勁增長推動,可減輕藥品集中採購的影響。
該行下調康哲藥業股份目標價,由26元降至20元,維持「買入」評級,並調低集團去年及今年收入預測分別19%及26%,每股盈利預測亦削18%及26%,反映藥品集中採購的影響及管理層最新指引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.